Invention Grant
US09045542B2 Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)
有权
通过Dectin-1或toll样受体2(TLR2)激活人类DCs来控制过敏和哮喘
- Patent Title: Controlling allergy and asthma by activating human DCs via Dectin-1 or toll-like receptor 2 (TLR2)
- Patent Title (中): 通过Dectin-1或toll样受体2(TLR2)激活人类DCs来控制过敏和哮喘
-
Application No.: US13596526Application Date: 2012-08-28
-
Publication No.: US09045542B2Publication Date: 2015-06-02
- Inventor: SangKon Oh , Jacques F. Banchereau , Gerard Zurawski , Hideki Ueno , Ling Ni
- Applicant: SangKon Oh , Jacques F. Banchereau , Gerard Zurawski , Hideki Ueno , Ling Ni
- Applicant Address: US TX Dallas
- Assignee: Baylor Research Institute
- Current Assignee: Baylor Research Institute
- Current Assignee Address: US TX Dallas
- Agency: Norton Rose Fulbright US LLP
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C07K16/00 ; C12P21/08 ; C07K16/28 ; C07K14/33 ; C07K14/47 ; C12N5/0784

Abstract:
The present invention includes compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of allergy, and asthma.
Public/Granted literature
- US20130052193A1 CONTROLLING ALLERGY AND ASTHMA BY ACTIVATING HUMAN DCs VIA DECTIN-1 OR TOLL-LIKE RECEPTOR 2 (TLR2) Public/Granted day:2013-02-28
Information query